Structure Therapeutics Inc. (GPCR)
NASDAQ: GPCR · Real-Time Price · USD
45.54
-0.66 (-1.43%)
Mar 27, 2026, 11:40 AM EDT - Market open
Structure Therapeutics Employees
Structure Therapeutics had 220 employees as of December 31, 2025. The number of employees increased by 57 or 34.97% compared to the previous year.
Employees
220
Change (1Y)
57
Growth (1Y)
34.97%
Revenue / Employee
n/a
Profits / Employee
-$641,827
Market Cap
3.23B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 220 | 57 | 34.97% |
| Dec 31, 2024 | 163 | 70 | 75.27% |
| Dec 31, 2023 | 93 | 25 | 36.76% |
| Dec 31, 2022 | 68 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,965 |
| ACADIA Pharmaceuticals | 798 |
| Crinetics Pharmaceuticals | 594 |
| Denali Therapeutics | 503 |
| Dyne Therapeutics | 258 |
| Alumis | 224 |
| Edgewise Therapeutics | 146 |
| Spyre Therapeutics | 102 |
GPCR News
- 3 hours ago - Structure Therapeutics: A High-Risk, High-Reward Bet On The Next GLP-1 Blockbuster - Seeking Alpha
- 10 days ago - Structure Therapeutics' GLP-1 Agonist Could Be A Potential Acquisition Target - Seeking Alpha
- 10 days ago - Structure Therapeutics Inc. (GPCR) Discusses Positive Topline Results from ACCESS II and Related Studies of Aleniglipron Oral GLP-1 Transcript - Seeking Alpha
- 11 days ago - Weight Loss Pill from Structure Therapeutics Trimmed the Most Pounds Yet. Is the Biotech a Takeover Candidate? - Barrons
- 11 days ago - Structure Therapeutics Stock Explodes As Much-Awaited Experimental Oral Drug Trial Shows Weight Loss Of 16% - Benzinga
- 11 days ago - Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron - GlobeNewsWire
- 4 weeks ago - Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights - GlobeNewsWire
- 5 weeks ago - Structure Therapeutics: The Dark Horse Has Taken The Lead - But Is It Enough? - Seeking Alpha